当前位置: 首页 >> 检索结果
1441. Spontaneous and Radiation-induced Mammary and Thyroid Tumorigenesis in LEW and (SD×COP)F1Brca1L63X/+ Rats.
作者: Yuzuki Nakamura.;Yukiko Nishimura-Yano.;Mayumi Nishimura.;Toshiaki Kokubo.;Kazuhiro Daino.;Masaru Takabatake.;Kento Nagata.;Tomoji Mashimo.;Shizuko Kakinuma.;Kazumasa Inoue.;Tatsuhiko Imaoka.
来源: Anticancer Res. 2025年45卷11期4869-4880页
Carriers of germline mutations in BRCA1/2 have an increased risk of carcinogenesis in breast, ovary, pancreas, stomach, etc. We previously established the Brca1 mutant (Brca1L63X/+) rat model on a Sprague-Dawley (SD) background, and it displayed an increased risk of mammary carcinoma during middle age after γ-ray exposure at 7 weeks of age. At younger ages, this model showed no increased risk of mammary tumors or other tumors, probably because of the relatively high susceptibility of the SD background to radiation-induced mammary carcinogenesis. Thus, we established new Brca1L63X/+ rat models on backgrounds with less susceptibility to mammary carcinogenesis and elucidated tumor risk in mammary tissue and other organs.
1442. Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia.
We previously reported the therapeutic potential of pimozide against adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type 1 (HTLV-1). Pimozide inhibits ubiquitin-specific protease 1 (USP1). In this study, we investigated the functional significance of USP1 and its potential as a therapeutic target for ATL treatment.
1443. Clearance of TP53 Mutations in ctDNA Reflects Therapeutic Response in Advanced Pancreatic Cancer Patients.
作者: Young Koog Cheon.;Sang Hoon Lee.;Dong Wook Kim.;Jung Hun Kim.;Se Min Kim.;Tae Yoon Lee.;Yeo-Min Yun.
来源: Anticancer Res. 2025年45卷11期4891-4907页
TP53 is one of the most frequently altered genes in pancreatic ductal adenocarcinoma (PDAC), yet its clinical significance as a predictive biomarker for treatment response remains unclear. The aim of study was to evaluate the feasibility of repeated ctDNA analysis and explore its potential relevance in predicting treatment outcomes by profiling the molecular evolution of PDAC patients during the 1st course of palliative chemotherapy.
1444. JI-CJ002, a Natural Herbal Formula, Enhances the Antitumor Efficacy of FOLFOX in Colorectal Cancer by Suppressing the DDR Pathway.
作者: Min-Woo Kim.;Daeun Kim.;Sang-Eun Lee.;Jaehak Ahn.;Byunghak Park.;Chunhoo Cheon.;Seong-Gyu Ko.
来源: Anticancer Res. 2025年45卷11期4987-5000页
Colorectal cancer (CRC) continues to pose substantial clinical challenges owing to the limited response and emergent resistance to standard chemotherapeutic regimens, including FOLFOX. The present investigation explored the antitumor efficacy of JI-CJ002, a standardized herbal formula consisting of Angelica gigas, Aconitum carmichaeli, and Zingiber officinale (2:1:3 ratio), and its combined effects with FOLFOX in in vitro settings.
1445. DDX39 Is Down-regulated in Chromophobe Renal Cell Carcinoma Tissues, Whereas Overexpression Is Associated With Shorter Patient Survival.
作者: Shin-Nosuke Yamashita.;Yoshiatsu Tanaka.;Shajedul Islam.;Takao Kitagawa.;Kazuhiro Tokuda.;Durga Paudel.;Sarita Giri.;Tohru Ohta.;Fumiya Harada.;Hiroki Nagayasu.;Yasuhiro Kuramitsu.
来源: Anticancer Res. 2025年45卷11期4743-4749页
Renal cell carcinoma (RCC) accounts for 85% of kidney tumors, and its incidence is rising. It includes 14 histological subtypes, notably clear cell (KIRC), papillary (KIRP), and chromophobe (KICH) RCC. While RCC generally has a favorable prognosis, the 5-year survival rate drops to ~12% with distant metastasis. Identifying prognostic markers is therefore crucial. DDX39, a DEAD-box RNA helicase, is up-regulated in various cancers, but its prognostic role in KIRP and KICH remains unclear. This study investigates the clinical relevance of DDX39 expression in KIRC, KIRP, and KICH using TCGA bioinformatics data.
1446. c-MYC Protein Expression Patterns in Laryngeal-Hypopharyngeal Squamous Cell Carcinomas.
作者: Sotirios Papouliakos.;Aristeidis Chrysovergis.;Vasileios Papanikolaou.;Dimitrios Tsounis.;Dimitrios Roukas.;Dimitrios Rigopoulos.;George Papanastasiou.;Evangelos Tsiambas.;Pavlos Pantos.;Nikolaos Poulianitis.;Andreas C Lazaris.;Nikolaos Kavantzas.;Efthymios Kyrodimos.
来源: Anticancer Res. 2025年45卷11期4933-4939页
Over activation of c-MYC oncogene (gene locus: 8q24.21) - predominantly due to the amplification of the gene - is a critical genetic imbalance involved in malignant transformation of normal epithelia. Our aim was to explore the differences in c-MYC protein expression in a series of laryngeal (LSCC) and hypopharyngeal squamous cell carcinomas (HPSCCs).
1447. RFC4 Drives Pancreatic Cancer Progression: Prognostic Relevance and Functional Evidence.
Replication Factor C (RFC) is a multisubunit complex involved in DNA replication and repair. Although RFC subunits have been associated with various cancers, their role in pancreatic cancer remains largely unknown. In this study, we analyzed the expression and clinical relevance of RFC4 in pancreatic adenocarcinoma using a publicly available database (GEPIA2). Subsequent functional assays were performed to validate its role in pancreatic cancer cells.
1448. Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway.
作者: Hye Min Kim.;Ju-Young Kim.;Chang Geun Lee.;Jie-Young Song.;Jong Kuk Park.;Jiyeon Ahn.;Chang-Woo Lee.;Seung Jin Han.;Sang-Gu Hwang.;Jeong-Hwa Baek.
来源: Anticancer Res. 2025年45卷11期4817-4826页
The limited efficacy of lung cancer treatment is partly due to the development of resistance to chemotherapy and radiotherapy. Recently, we identified Nodal modulators (NOMO1, NOMO2, and NOMO3), proteins involved in early embryonic patterning, as key factors in the radioresistance of lung cancer cells. Although NOMO proteins are highly expressed in lung cancer tissues, their roles in lung cancer have yet to be sufficiently determined.
1449. Osteosclerosis and Meningioma: Implicating the Tumor Suppressor Gene AMER1/WTX.
作者: Ashwin Kumaria.;Peter Weir.;Robert Goldspring.;Ian Scott.;Alex Leggate.
来源: Anticancer Res. 2025年45卷11期5233-5237页
Meningiomas are common intracranial tumors with variable biological behavior and incompletely understood molecular drivers, particularly in sporadic cases.
1450. Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax.
作者: Yasufumi Ito.;Kazuki Nakamura.;Yurika Nakagawa-Saito.;Senri Takenouchi.;Shuhei Suzuki.;Keita Togashi.;Asuka Sugai.;Yuta Mitobe.;Manabu Seino.;Tsuyoshi Ohta.;Satoru Nagase.;Chifumi Kitanaka.;Masashi Okada.
来源: Anticancer Res. 2025年45卷11期4841-4851页
Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer characterized by infrequent TP53 mutations. We recently reported that the MDM4 inhibitor CEP-1347 effectively activated the p53 - p21 axis and inhibited the proliferation of OCCC cells with wild-type TP53. We also recently found that CEP-1347 induced senescence-like phenotypes in glioma stem cells and sensitized them to senolytics, such as BH3 mimetics represented by navitoclax. In the present study, we investigated whether CEP-1347 induced senescence-like phenotypes in OCCC cells and if combinations with BH3 mimetics enhanced the anti-cancer activity of CEP-1347 by promoting senolysis in OCCC cells.
1451. Pathological Complete Response in Locally-advanced MSI-H/dMMR Sigmoid Colon Cancer Treated With Pembrolizumab and Abdominal Reconstruction.
作者: Masashi Shimasaki.;Yuki Kiyozumi.;Ryota Ohmura.;Kozue Matsuishi.;Tomo Horinouchi.;Toshihiko Yusa.;Masayo Tsukamoto.;Taisuke Yagi.;Takayoshi Kaida.;Kota Arima.;Kenji Shimizu.;Kensuke Yamamura.;Kensuke Sakata.;Yasuo Sakamoto.;Hisanobu Oda.;Takihiro Kamio.;Katsunori Imai.
来源: Anticancer Res. 2025年45卷11期5239-5246页
Microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) colorectal cancers have shown significant responses to immune checkpoint inhibitors such as pembrolizumab, presenting novel opportunities for potentially curative strategies in cases previously deemed unresectable.
1452. Contribution of Xeroderma Pigmentosum Complementation Group C Genotypes to Colorectal Cancer in Taiwanese.
作者: Yuh-Feng Tsai.;Ming-Hsien Wu.;Tzu-Chieh Lin.;Te-Cheng Yueh.;Hou-Yu Shih.;Yun-Chi Wang.;Jai-Sing Yang.;Yi-Chih Hung.;Tao-Wei Ke.;Chia-Wen Tsai.;DA-Tian Bau.;Wen-Shin Chang.
来源: Anticancer Res. 2025年45卷11期4751-4763页
Xeroderma pigmentosum complementation group C (XPC) is reported to play important roles in DNA integrity and genomic instability, however, the contribution of XPC to colorectal cancer (CRC) carcinogenesis is largely uncertain. Therefore, we aimed to examine the potential associations of XPC rs2228000 and rs2228001 genotypes and CRC susceptibility in a Taiwanese cohort.
1453. MGMT Promoter Methylation in Glioblastoma Stem Cells: Stability During Differentiation and Comparison With Surgically-resected Tumors.
作者: Masaki Yoshioka.;Shunsei Noguchi.;Yasuo Iwadate.;Masayoshi Kobayashi.;Shinichiro Motohashi.;Yoshinori Higuchi.
来源: Anticancer Res. 2025年45卷11期4959-4969页
The prognosis and resistance to temozolomide in glioblastoma have been evaluated based on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation using bulk tumor samples resected via surgery. However, it remains unclear whether MGMT promoter methylation differs between glioblastoma stem cells and the overall tumor within the patient's brain. Chemoresistance of glioblastoma stem cells is a critical factor in understanding the refractory nature of the disease. This study aimed to assess MGMT promoter methylation in glioblastoma stem cells and compare it with that in differentiated tumor cells.
1454. Impact of Interleukin-12B Genotypes on Breast Cancer Risk.
作者: Chih-Chiang Hung.;Yun-Chi Wang.;Chia-Hua Liu.;Meng-Liang Lin.;Shih-Shun Chen.;Hou-Yu Shih.;Ya-Chen Yang.;Te-Chun Hsia.;Chen-Hsien Su.;Wen-Shin Chang.;DA-Tian Bau.;Chia-Wen Tsai.
来源: Anticancer Res. 2025年45卷11期4771-4781页
Breast cancer (BC) remains the leading cause of cancer-related mortality among women worldwide. Interleukin-12 (IL-12), a cytokine pivotal in immune regulation, has shown antitumor properties and may contribute to BC pathogenesis.
1455. Efficient Inhibition of FOXM1 Expression and Viability of High-grade Meningioma Cells by Domatinostat-mediated Dual Targeting of HDAC1 and HDAC2.
作者: Kazuki Nakamura.;Yasufumi Ito.;Yurika Nakagawa-Saito.;Senri Takenouchi.;Shuhei Suzuki.;Keita Togashi.;Asuka Sugai.;Yuta Mitobe.;Yukihiko Sonoda.;Chifumi Kitanaka.;Masashi Okada.
来源: Anticancer Res. 2025年45卷11期4853-4868页
High-grade meningiomas are tumors with high recurrence rates and poor prognoses, and the development of effective pharmacological therapies remains a major challenge. Forkhead box protein M1 (FOXM1), a transcription factor known to play a key role in the malignancy of high-grade meningiomas, has gained attention as a potential therapeutic target. Class I histone deacetylase (HDAC) inhibitors have been shown to suppress FOXM1 expression and cell proliferation in various cancers; however, their efficacy in high-grade meningiomas remains unclear. The present study investigated the role of class I HDACs in regulating FOXM1 expression and cell proliferation in high-grade meningioma cell lines and examined the effects of the class I HDAC inhibitor domatinostat on FOXM1 expression and cell proliferation in these cell lines.
1456. Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer.
作者: Ayumu Hosokawa.;Rin Yamada.;Yukiko Otsuki.;Hotaka Tamura.;Akiko Ichihara.;Tsuyoshi Fukushima.;Yoshihiro Komohara.
来源: Anticancer Res. 2025年45卷11期5069-5076页
Immune checkpoint inhibitors have demonstrated significant clinical efficacy in patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer. Although current evidence is based on studies with limited sample sizes, recent findings suggest that anti-programmed cell death-1 (PD-1) antibodies are highly effective in patients with locally advanced dMMR/MSI-H rectal cancer.
1457. Mendelian Randomization Studies on Actinic Keratosis.
作者: Ida M Heerfordt.;Frederik Viggo Lautrup Esmann.;Henrik Horwitz.
来源: Anticancer Res. 2025年45卷11期4683-4687页
Actinic keratosis (AK) is a common skin condition associated with cumulative sun exposure and advancing age. As a precursor to squamous cell carcinoma, it is clinically relevant as a target for prevention. While epidemiological studies have suggested various risk factors, causal inference is often limited by confounding. Mendelian randomization (MR), which uses genetic variants as proxies for exposures, can help address this. This review aimed to provide an overview of published MR studies that have examined AK either as an exposure or an outcome.
1458. Differential Proteomic Analysis of DEN-induced Hepatocellular Carcinoma in Male and Female Balb/c Mice Reveals Novel Sex-Specific Markers.
作者: Salmma Salamah Salihah.;Muhammad Tahir.;Bareera Bibi.;Rabia Sultan.;Martin R Larsen.;Munazza Raza Mirza.;Sana Mahmood.;Muhammad Rizwan Alam.;Jamila Iqbal.;William C Cho.;Asma Gul.
来源: Cancer Genomics Proteomics. 2025年22卷6期912-928页
Hepatocellular carcinoma (HCC) is one of the leading causes of hepatic malignancy with a higher prevalence in males compared to females; however, the distinct underlying mechanisms contributing to this disparity remain poorly understood.
1459. BMP1 Appears to be Involved in GPER1-mediated Progression and Tamoxifen Resistance of Luminal A Breast Cancer Cells.
作者: Katharina Wert.;Johanna Jentsch.;Julia Gallwas.;Carsten Gründker.
来源: Cancer Genomics Proteomics. 2025年22卷6期900-911页
Bone morphogenetic protein 1 (BMP1) plays a role in the activation of both transforming growth factor-β (TGFβ) and BMP signaling pathways. We investigated whether BMP1 is involved in G-protein coupled estrogen receptor 1 (GPER1)-regulated progression of luminal A-type breast cancer cells.
1460. Lower SYNJ2BP Gene Expression Is Associated With Poor Survival Outcome and Treatment Response in Clear Cell Renal Cell Carcinoma: A Bioinformatics Analysis.
作者: Marilyn D Saulsbury.;Simone O Heyliger.;Emanuela Taioli.;Tamiel N Turley.;Jordan P Reynolds.;John A Copland.;Adam M Kase.;R Renee Reams.
来源: Cancer Genomics Proteomics. 2025年22卷6期863-881页
Clear cell renal cell carcinoma (ccRCC), the most prevalent form of kidney cancer, often presents or recurs as an advanced, aggressive, and lethal disease. Thus, biomarkers are needed to identify patients at risk of developing advanced-stage or treatment-resistant ccRCC. SYNJ2BP, a cytoplasmic scaffolding protein, regulates ACVR2 activity, a key mediator of signaling pathways involved in tumor progression and metastasis. This study aimed to ascertain if SYNJ2BP, a gene highly expressed in normal kidney tissue, may serve as a predictive biomarker for ccRCC.
|